Last updated: March 13, 2026
What is NDC 66993-0168?
NDC 66993-0168 is a prescription drug marketed under the brand name Vesomni. It is primarily used for the treatment of chronic insomnia in adults. Vesomni combines eszopiclone (a sedative-hypnotic agent) and melatonin (a sleep-regulating hormone), offering a dual approach to managing sleep disorders.
Market Size and Demand Drivers
The global sleep aids market was valued at approximately USD 4.5 billion in 2022 and is projected to reach USD 6.7 billion by 2028, growing at a CAGR of 6.5% (2018-2028). The rise in sleep disorder prevalence, driven by aging populations and increasing mental health awareness, fuels demand.
Key factors influencing demand:
-
Aging population: Older adults commonly experience insomnia. The U.S. Census projects those over 65 will constitute 21% of the population by 2030.
-
Increasing mental health concerns: Sleep disturbances link to depression, anxiety, and stress-related disorders.
-
Premium-priced combination therapy: Vesomni's dual mechanism targets a broader patient base, especially those refractory to monotherapy.
Competitive landscape:
Major competitors include:
-
Ambien (zolpidem): USD 615 million in U.S. sales in 2022 [1].
-
Lunesta (eszopiclone): USD 250 million in U.S. sales in 2022 [2].
-
Belsomra (suvorexant): USD 200 million in 2022 [3].
Vesomni, with its novel formulation, might capture segments seeking synergistic effects and improved sleep quality.
Pricing Analysis
Current pricing benchmarks:
| Drug |
Average Wholesale Price (AWP) |
Estimated Monthly Cost (for a 30-day supply) |
| Ambien |
USD 10.50 per tablet (10 mg, 30 tabs) |
USD 315 (assuming 1 tablet/night) |
| Lunesta |
USD 20 per tablet (3 mg, 30 tabs) |
USD 600 (assuming 1 tablet/night) |
| Belsomra |
USD 25 per tablet (10 mg, 30 tabs) |
USD 750 |
Vesomni's price point is projected to be between USD 700 and USD 900 per month, reflecting its combination product status and potential for premium positioning.
Price projection considerations:
-
Market entry price: USD 750 per month.
-
Potential discounts: Negotiated rebates with insurers could lower net prices by 20-30%.
-
Price erosion factors: Competition from generics (when patents expire), genericization of eszopiclone, and changing reimbursement policies.
Patent and Regulatory Data
Vesomni's patent extends to at least 2030, granting exclusivity in the U.S. [4]. The drug obtained FDA approval in Q1 2023, with a launch in Q2 2023.
Revenue Projections (2023–2028)
Assuming the following:
-
Year 1 sales: USD 100 million, capturing 2% market share in the sleep aids segment.
-
Annual growth rate: 20% due to increasing adoption and demand.
| Year |
Projected Revenue |
Notes |
| 2023 |
USD 100 million |
Launch year, early adoption phase |
| 2024 |
USD 120 million |
Increased prescribing, expanded insurer coverage |
| 2025 |
USD 144 million |
Wider clinician familiarity, growth in elderly population |
| 2026 |
USD 173 million |
Possible entry of generics, slight price competition |
| 2027 |
USD 208 million |
Established brand, market penetration continues |
Key Market Risks
-
Patent cliffs: Patent expiration could lead to generic competition.
-
Reimbursement policies: Shifts toward value-based pricing could pressure margins.
-
Regulatory hurdles: FDA new safety warnings or label changes could impact sales.
Strategic Recommendations
-
Focus on developing robust value-based contracts to secure reimbursement.
-
Invest in clinical trials demonstrating superior efficacy to justify premium pricing.
-
Prepare for potential patent challenges or generics by extending formulation patents.
Key Takeaways
-
Vesomni faces a competitive sleep aids market with a substantial growth trajectory.
-
Launch pricing is projected around USD 750/month, with significant upside from demand growth.
-
Market share assumptions suggest USD 100 million in initial revenue, scaling to over USD 200 million within five years.
-
Patent exclusivity remains a critical factor until at least 2030; competitive pressures from generics are foreseeable thereafter.
FAQs
Q1: How does Vesomni’s pricing compare with existing sleep medications?
It is positioned slightly higher than Ambien but lower than Belsomra, reflecting its combination therapy status and potential premium efficacy.
Q2: What is the main differentiator of Vesomni in the sleep aid market?
Its dual mechanism combining eszopiclone and melatonin addresses both sleep initiation and circadian rhythm regulation.
Q3: What factors could impact Vesomni's market penetration?
Patent expiry, generic competition, insurer formulary decisions, and clinician prescribing habits.
Q4: How will market growth rates influence revenue projections?
A 20% annual growth rate assumes steady demand; deviations due to market saturation or competition could alter projections.
Q5: Are there significant regulatory risks?
Regulatory agencies can impose safety warnings or updated labeling, which may affect sales or reimbursement terms.
References
- IMS Health. (2023). U.S. prescription sales data.
- SSR Health. (2023). Prescription drug sales figures.
- IQVIA. (2023). Monthly pharmaceutical market report.
- FDA. (2023). Vesomni Drug Approval and Patent Status.
